Literature DB >> 20013614

Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series.

G Paslakis, M Gilles, A Meyer-Lindenberg, M Deuschle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20013614     DOI： 10.1055/s-0029-1237375

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN： 0176-3679            Impact factor:   5.788


× No keyword cloud information.
  18 in total

1.  CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy.

Authors:  Anita J Bechtholt-Gompf; Karen L Smith; Catherine S John; Hannah H Kang; William A Carlezon; Bruce M Cohen; Dost Ongür
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

2.  New use for an old drug: oral ketamine for treatment-resistant depression.

Authors:  Kevin M Swiatek; Kim Jordan; Julie Coffman
Journal:  BMJ Case Rep       Date:  2016-08-03

Review 3.  Glutamatergic Modulators in Depression.

Authors:  Ioline D Henter; Rafael Teixeira de Sousa; Carlos A Zarate
Journal:  Harv Rev Psychiatry       Date:  2018 Nov/Dec       Impact factor: 3.732

4.  Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study.

Authors:  Laura Kranaster; Jutta Kammerer-Ciernioch; Carolin Hoyer; Alexander Sartorius
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-03-13       Impact factor: 5.270

Review 5.  Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression.

Authors:  Ioline D Henter; Rafael T de Sousa; Philip W Gold; Andre R Brunoni; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Expert Rev Clin Pharmacol       Date:  2017-01-16       Impact factor: 5.045

Review 6.  Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.

Authors:  Nicolas D Iadarola; Mark J Niciu; Erica M Richards; Jennifer L Vande Voort; Elizabeth D Ballard; Nancy B Lundin; Allison C Nugent; Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  Ther Adv Chronic Dis       Date:  2015-05       Impact factor: 5.091

Review 7.  Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.

Authors:  John H Krystal; Gerard Sanacora; Ronald S Duman
Journal:  Biol Psychiatry       Date:  2013-06-15       Impact factor: 13.382

8.  Novel Glutamatergic Treatments for Severe Mood Disorders.

Authors:  Minkyung Park; Mark J Niciu; Carlos A Zarate
Journal:  Curr Behav Neurosci Rep       Date:  2015-10-09

9.  Depletion of serotonin in the basolateral amygdala elevates glutamate receptors and facilitates fear-potentiated startle.

Authors:  L Tran; B K Lasher; K A Young; N B Keele
Journal:  Transl Psychiatry       Date:  2013-09-03       Impact factor: 6.222

10.  Ketamine as antidepressant? Current state and future perspectives.

Authors:  H W W Hasselmann
Journal:  Curr Neuropharmacol       Date:  2014-01       Impact factor: 7.363
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.